ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1474

Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis

Xiaochun Liu1, Maureen D. Mayes1, Filemon K. Tan1, Minghua Wu1, John D. Reveille2, Brock E. Harper3, Hilda T. Draeger4, Emilio B. Gonzalez5 and Shervin Assassi6, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, 3Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, 4Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, 5Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 6Rheumatology, Univ of Texas Health Science Houston, Houston, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chemokines, interferons and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Plasma Interferon Inducible Chemokine Score: Stable Marker of Disease Severity in Systemic Sclerosis

ABSTRACT:

Background/Purpose: The most prominent gene expression profile in the peripheral blood of patients with systemic sclerosis (SSc) is an interferon (IFN) inducible signature.  A large scale correlation of this signature with disease subtypes and features has not been performed due to scarcity of RNA samples.  Herein, we identify plasma chemokines that correlate strongly with the IFN gene signature and investigate their correlation with disease features in a large early SSc cohort.   

Methods: We examined the correlation of IFNγ-inducible protein-10 (IP-10/CXCL10), IFN-inducible T cell alpha chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein-1 (MCP-1/CCL2) with the IFN gene expression signature.  We generated an IFN-inducible chemokine score with the correlated chemokines, IP-10 and I-TAC, and compared it in 266 patients enrolled in the GENISOS cohort (disease duration<5 years, 59% diffuse cutaneous involvement) to that of 97 matched controls.  Subsequently, the correlation between the baseline chemokine score and markers of disease severity was assessed.  Finally, the course of chemokine score over time was examined in 63 follow-up plasma samples prospectively.

Results: The plasma IFN-inducible chemokine score highly correlated with the IFN-inducible gene expression signature (rs=0.612, p=0.0015) and was significantly higher in SSc patients than matched controls (p<0.001).  When the chemokine level was dichotomized based on the 95th percentile level in unaffected controls, 39.2% of patients had a positive chemokine score, which is more prevalent than any SSc-related autoantibody. Furthermore, the chemokine score was associated with the presence of anti–U1 ribonucleoprotein antibodies (RNP) (p<0.001) and absence of anti–RNA polymerase III antibodies (p=0.002), but not disease duration, disease type, or other autoantibodies.  As shown in Table 1, the chemokine score correlated with the concomitantly obtained muscle, skin and lung components of the Medsger Severity Index, as well as, FVC, DLco, creatine kinase independent of anti-RNP or other potential confounders (age, gender, ethnicity, disease duration, and treatment with immunosuppressive agents).  Finally, there were no significant changes in the chemokine scores over time while their baseline levels correlated significantly with those on the follow-up visits (r=0.39, p=0.002).  This indicates that the chemokine score is a stable marker of disease severity and does not fluctuate in a consistent time-dependent manner.

Conclusion: The IFN-inducible chemokine score is a stable marker of more severe subtype of SSc.  This composite score may be useful for risk stratification regardless of disease type, serology or duration. It also might identify the subgroup of patients that benefit from treatments targeting IFN pathways.

 


Disclosure:

X. Liu,
None;

M. D. Mayes,
None;

F. K. Tan,
None;

M. Wu,
None;

J. D. Reveille,
None;

B. E. Harper,
None;

H. T. Draeger,
None;

E. B. Gonzalez,
None;

S. Assassi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-inducible-chemokines-correlate-with-disease-severity-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology